All In Biotech

Drug Trial Radar · NCT00263042

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors

Last checked: Nov 20, 2026Latest source record: May 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 18,695 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

18,695

Actual

Start

Dec 2005

Primary completion

Apr 2009

Study completion Apr 2009

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors. The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV death, or CV hospitalization in these patients.

Conditions

  • Cardiovascular Disease

Interventions

  • RimonabantDrug

    Tablet, oral administration

  • Placebo (for Rimonabant)Drug

    Tablet, oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First occurrence of any of myocardial infarction, stroke or cardiovascular (CV) deathTime frame: From randomization up to common study end date (33-50 months)

Locations

43 sites in 43 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Bridgewater, New Jersey

  • Sanofi-Aventis Administrative Office

    Buenos Aires, Argentina

  • sanofi-aventis Australia & New Zealand administrative office

    Macquarie Park, New South Wales, Australia

  • Sanofi-Aventis Administrative Office

    Vienna, Austria

  • Sanofi-Aventis Administrative Office

    Diegem, Belgium

  • Sanofi-Aventis Administrative Office

    São Paulo, Brazil

  • Sanofi-Aventis Administrative Office

    Laval, Quebec, Canada

  • Sanofi-Aventis Administrative Office

    Santiago, Chile

  • Sanofi-Aventis Administrative Office

    Shangaï, China

  • Sanofi-Aventis Administrative Office

    Bogotá, Colombia

  • Sanofi-Aventis Administrative Office

    Prague, Czechia

  • Sanofi-Aventis Administrative Office

    Hørsholm, Denmark

  • Sanofi-Aventis Administrative Office

    Helsinki, Finland

  • Sanofi-Aventis Administrative Office

    Paris, France

  • Sanofi-Aventis Administrative Office

    Berlin, Germany

  • Sanofi-Aventis Administrative Office

    Athens, Greece

  • Sanofi-Aventis Administrative Office

    Hong Kong, Hong Kong

  • Sanofi-Aventis Administrative Office

    Budapest, Hungary

  • Sanofi-Aventis Administrative Office

    Mumbai, India

  • Sanofi-Aventis Administrative Office

    Dublin, Ireland

  • Sanofi-Aventis Administrative Office

    Netanya, Israel

  • Sanofi-Aventis Administrative Office

    Milan, Italy

  • Sanofi-Aventis Administrative Office

    Kuala Lumpur, Malaysia

  • Sanofi-Aventis Administrative Office

    México, Mexico

  • Sanofi-Aventis Administrative Office

    Gouda, Netherlands

  • Sanofi-Aventis Administrative Office

    Lysaker, Norway

  • Sanofi-Aventis Administrative Office

    Lima, Peru

  • Sanofi-Aventis Administrative Office

    Makati City, Philippines

  • Sanofi-Aventis Administrative Office

    Warsaw, Poland

  • Sanofi-Aventis Administrative Office

    Porto Salvo, Portugal

  • Sanofi-Aventis Administrative Office

    Bucharest, Romania

  • Sanofi-Aventis Administrative Office

    Moscow, Russia

  • Sanofi-Aventis Administrative Office

    Singapore, Singapore

  • Sanofi-Aventis Administrative Office

    Midrand, South Africa

  • Sanofi-Aventis Administrative Office

    Seoul, South Korea

  • Sanofi-Aventis Administrative Office

    Madrid, Spain

  • Sanofi-Aventis Administrative Office

    Bromma, Sweden

  • Sanofi-Aventis Administrative Office

    Geneva, Switzerland

  • Sanofi-Aventis Administrative Office

    Taipei, Taiwan

  • Sanofi-Aventis Administrative Office

    Bangkok, Thailand

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.